Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart fail
- PDF / 1,246,797 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 2 Downloads / 147 Views
RESEARCH
Open Access
Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart failure therapy Janine A. M. Kamphuis1*, Marijke Linschoten1, Maarten J. Cramer1, Pieter A. Doevendans1,2,3, Folkert W. Asselbergs1,4,5 and Arco J. Teske1
Abstract Background: Anthracycline-induced cardiac dysfunction (ACD) is a notorious side effect of anticancer treatment. It has been described as a phenomenon of a continuous progressive decline of cardiac function, eventually leading to dilated cardiomyopathy (DCM). This progressive nature suggests that patients with a delayed ACD diagnosis have greater compromise of cardiac function and more adverse remodeling, with a poor response to heart failure (HF) treatment. This study aimed to delineate the impact of a delayed ACD diagnosis on echocardiographic characteristics and response to HF treatment. Methods and results: From the population of our cardio-oncology outpatient clinic, 92 ACD patients were included in this study (age 51.6 ± 16.2 years, median cumulative anthracycline dose 329 [200–329] mg/m2), and a median follow-up of 25.0 [9.6–37.2] months after ACD diagnosis. Median time to ACD diagnosis for patients diagnosed early (< 1 year) and late (> 1 year) was 4.0 vs. 47.7 months respectively. There were no echocardiographic differences between patients diagnosed early vs. late (LVEF 43.6 ± 4.9% vs. 43.0 ± 6.2% and iEDV 63.6 vs. 62.9 mL/ m2). Eighty-three percent of patients presented with mild LV dysfunction and in 79% the LV was not dilated. Patients diagnosed early were more likely to have (partial) recovery of cardiac function upon HF treatment initiation (p = 0.015). Conclusions: In the setting of a cardio-oncology outpatient clinic, patients with ACD presented with a hypokinetic non-dilated cardiomyopathy, rather than typical DCM. Timing of ACD diagnosis did not impact HF disease severity. However, in patients receiving an early diagnosis, cardiac function was more likely to recover upon HF treatment. Keywords: Heart failure, Anthracyclines, Cardiac dysfunction, Cardiac effects of cancer treatment
* Correspondence: [email protected] 1 Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, University of Utrecht, E03.511, PO Box 85500, 3508 GA Utrecht, The Netherlands Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended
Data Loading...
